Shots:
- The EC has approved AbbVie‘s Aquipta (atogepant) for the acute treatment of migraine in adults with or without aura, to be taken as needed
- Approval was supported by the P-III (ECLIPSE) trial data assessing Aquipta/Qulipta (60mg, PO) vs PBO as an acute treatment of migraine with or without aura in 1,328 adults (18-75yrs.)
- Trial met its 1EP, with Aquipta achieving pain freedom 2hrs. after the first migraine attack. It also showed improvements across key 2EPs, incl. freedom from the most bothersome symptom, pain relief, reduced rescue medication use, & sustained pain freedom up to 48hrs., with consistent efficacy across multiple attacks
Ref: PRnewswire | Image: AbbVie | Press Release
Related News: AbbVie Reports the US FDA Approval for Decnupaz to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
